UB Paderborn / Katalog / Suche / in CDI

A Genome-wide Association Study of Dupuytren Disease Reveals 17 Additional Variants Implicated in Fibrosis

American journal of human genetics, 2017-09, Vol.101 (3), p.417-427

2017

Link zum Volltext

Verfügbarkeit prüfen

Gene expression profiles of changes underlying different-sized human rotator cuff tendon tears

Journal of shoulder and elbow surgery, 2016-10, Vol.25 (10), p.1561-1570

2016

Link zum Volltext

Verfügbarkeit prüfen

Considerations for treatment duration in responders to immune checkpoint inhibitors

Journal for immunotherapy of cancer, 2021-03, Vol.9 (3), p.e001901

2021

Link zum Volltext

Verfügbarkeit prüfen

Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner

Journal for immunotherapy of cancer, 2022-02, Vol.10 (2), p.e003382

2022

Link zum Volltext

Verfügbarkeit prüfen

LSO-006 Targeting pathogenic auto-reactive VH4-34 B cells with a rationally developed and highly specific anti-VH4-34 antibody offers a new therapeutic approach for VH4-34 autoimmune disorders

Lupus science & medicine, 2023-07, Vol.10 (Suppl 1), p.A37-A37

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1889: Dual-specific antibodies that bind to BCMA and TACI (HMBD-009) enable better targeting of multiple myeloma in pre-clinical models

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1889-1889

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract P197: An anti-HER3 antibody, HMBD-001, that uniquely binds to and blocks the HER3 heterodimerization interface, shows superior tumor growth inhibition in biomarker-defined preclinical cancer models including NRG1-fusion driven cancers

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P197-P197

2021

Link zum Volltext

Verfügbarkeit prüfen

HMBD-002 is a novel, neutralizing, anti-VISTA antibody exhibiting strong preclinical efficacy and safety, being developed as a monotherapy and in combination with pembrolizumab

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e14569-e14569

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 587: HMBD002, a novel neutralizing antibody targeting a specific epitope on the co-inhibitory immune checkpoint receptor VISTA, displays potent anti-tumor effects in pre-clinical models

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.587-587

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 24: HMBD001, a novel anti-ErbB3 antibody with a unique mechanism of action, effectively inhibits tumor growth in pre-clinical models of ErbB3+ solid tumors

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.24-24

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1729: Integrative immune profiling of syngeneic tumor models provides predictive immune signatures for treatment response with HMBD002, a novel anti-VISTA neutralizing antibody

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1729-1729

2018

Link zum Volltext

Verfügbarkeit prüfen

HMBD004, a Novel Anti-CD47xCD33 Bispecific Antibody Displays Potent Anti-Tumor Effects in Pre-Clinical Models of AML

Blood, 2017-12, Vol.130, p.1378-1378

2017

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS2664-TPS2664

2023

Link zum Volltext

Verfügbarkeit prüfen

10D1F, an Anti-HER3 Antibody that Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models

Molecular cancer therapeutics, 2020-02, Vol.19 (2), p.490-501

2020

Link zum Volltext

Verfügbarkeit prüfen

Distribution and expression of type VI collagen and elastic fibers in human rotator cuff tendon tears

Connective tissue research, 2014-10, Vol.55 (5-6), p.397-402

2014

Link zum Volltext

Verfügbarkeit prüfen

532 Anti-VISTA antibody HMBD-002 reprograms tumour associated macrophages and promotes cytotoxic T cell response

Journal for immunotherapy of cancer, 2022, Vol.10 (Suppl 2), p.A558-A558

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2659: Anti-HER3 antibody, HMBD-001, in combination with an EGFR inhibitor effectively inhibits tumor growth in biomarker-selected pre-clinical models of squamous cell carcinomas

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2659-2659

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2660: HMBD-501 - a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate shows robust efficacy and tolerability in pre-clinical solid tumor models

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2660-2660

2023

Link zum Volltext

Verfügbarkeit prüfen

469 A phase 1 first in human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A498-A498

2021

Link zum Volltext

Verfügbarkeit prüfen

sensitization of glioma cells to cisplatin and tamoxifen by the use of catechin

Molecular biology reports, 2009-05, Vol.36 (5), p.1181-1186

2009

Link zum Volltext

Verfügbarkeit prüfen

Proteomic Studies Coupled with RNAi Methodologies can Shed Further Light on the Downstream Effects of Telomerase in Glioma

Cancer investigation, 2011-02, Vol.29 (2), p.113-122

2011

Link zum Volltext

Verfügbarkeit prüfen

Proteomics: the tool to bridge the gap between the facts and fables of telomerase

Critical reviews in oncogenesis, 2008, Vol.14 (4), p.203

2008

Link zum Volltext

Verfügbarkeit prüfen

Can hsp90α-Targeted siRNA Combined With TMZ Be a Future Therapy for Glioma?

Cancer investigation, 2010-06, Vol.28 (6), p.608-614

2010

Link zum Volltext

Verfügbarkeit prüfen

Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma?

Cancer investigation, 2010-07, Vol.28 (6), p.608

2010

Link zum Volltext

Verfügbarkeit prüfen

Arylidene analogues as selective COX-2 inhibitors: synthesis, characterization, in silico and in vitro studies

Journal of biomolecular structure & dynamics, 2021-12, Vol.39 (18), p.7150-7159

2021

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

A Genome-wide Association Study of Dupuytren Disease Reveals 17 Additional Variants Implicated in Fibrosis

Gene expression profiles of changes underlying different-sized human rotator cuff tendon tears

Considerations for treatment duration in responders to immune checkpoint inhibitors

Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner

LSO-006 Targeting pathogenic auto-reactive VH4-34 B cells with a rationally developed and highly specific anti-VH4-34 antibody offers a new therapeutic approach for VH4-34 autoimmune disorders

Abstract 1889: Dual-specific antibodies that bind to BCMA and TACI (HMBD-009) enable better targeting of multiple myeloma in pre-clinical models

Abstract P197: An anti-HER3 antibody, HMBD-001, that uniquely binds to and blocks the HER3 heterodimerization interface, shows superior tumor growth inhibition in biomarker-defined preclinical cancer models including NRG1-fusion driven cancers

HMBD-002 is a novel, neutralizing, anti-VISTA antibody exhibiting strong preclinical efficacy and safety, being developed as a monotherapy and in combination with pembrolizumab

Abstract 587: HMBD002, a novel neutralizing antibody targeting a specific epitope on the co-inhibitory immune checkpoint receptor VISTA, displays potent anti-tumor effects in pre-clinical models

Abstract 24: HMBD001, a novel anti-ErbB3 antibody with a unique mechanism of action, effectively inhibits tumor growth in pre-clinical models of ErbB3+ solid tumors

Abstract 1729: Integrative immune profiling of syngeneic tumor models provides predictive immune signatures for treatment response with HMBD002, a novel anti-VISTA neutralizing antibody

HMBD004, a Novel Anti-CD47xCD33 Bispecific Antibody Displays Potent Anti-Tumor Effects in Pre-Clinical Models of AML

A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors

10D1F, an Anti-HER3 Antibody that Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models

Distribution and expression of type VI collagen and elastic fibers in human rotator cuff tendon tears

532 Anti-VISTA antibody HMBD-002 reprograms tumour associated macrophages and promotes cytotoxic T cell response

Abstract 2659: Anti-HER3 antibody, HMBD-001, in combination with an EGFR inhibitor effectively inhibits tumor growth in biomarker-selected pre-clinical models of squamous cell carcinomas

Abstract 2660: HMBD-501 - a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate shows robust efficacy and tolerability in pre-clinical solid tumor models

469 A phase 1 first in human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies

sensitization of glioma cells to cisplatin and tamoxifen by the use of catechin

Proteomic Studies Coupled with RNAi Methodologies can Shed Further Light on the Downstream Effects of Telomerase in Glioma

Proteomics: the tool to bridge the gap between the facts and fables of telomerase

Can hsp90α-Targeted siRNA Combined With TMZ Be a Future Therapy for Glioma?

Can hsp90alpha-targeted siRNA combined with TMZ be a future therapy for glioma?

Arylidene analogues as selective COX-2 inhibitors: synthesis, characterization, in silico and in vitro studies

Suchergebnisse filtern